This former standalone antithrombotic page has been folded into ASCVD / Lp(a) Prevention Master and Medication List + Hard Avoids. It remains as a short preserved pointer because aspirin/antiplatelet safety is link-sensitive.
cardiovascular · antithrombotics · lp(a) · gi-bleeding · archived
This page is no longer the active owner. Its aspirin/high-Lp(a) evidence summary and high-bleeding-risk net-benefit rule were folded into ASCVD / Lp(a) Prevention Master on 2026-05-10, with medication safety still cross-linked from Medication List + Hard Avoids.
Preserved core rule, updated after old papers were found: no self-directed aspirin or antiplatelet even though 2024 RPPH Doppler documents mild right-leg PAD/peripheral plaque. Very high Lp(a) plus plaque makes antiplatelet logic tempting, but prior diverticular hemorrhage plus stool-blood/iron history makes bleeding risk real. Antithrombotics are a cardiology + GI decision, especially if obstructive CAD, MI, stroke/TIA, stent, progressive/symptomatic PAD, or clinician-defined chronic coronary disease is documented.
Full original text is preserved in archive/ascvd-lpa-prevention-originals-2026-05-10.md.